Table 2.
Frequencies of NK/T-cell Lymphoma, nasal type, and aggressive NK-cell leukemia in previous published series
| Series | Origin | NKTCL | ANKCL | NKTCL + ANKCL | [References] |
|---|---|---|---|---|---|
|
NK-cell Tumor Study Group * |
Asia (Japan) |
150 (87.2%) |
22 (12.8%) |
172 (100%) |
[37] |
| Nasal: 123 (82.0%) | |||||
| Extranasal: 27 (18.0%) | |||||
|
International Peripheral T-Cell Lymphoma Project (IPTCLP)
group** |
North America, Europe, and Asia |
127 (98.5%) |
2 (1.5%) |
129 (100%) |
[35] |
| Nasal: 92 (72.4%) | |||||
| Extranasal: 35 (27.6%) | |||||
|
Brazilian group |
South America (Brazil) |
120 (100%) |
0 (0%) |
120 (100%) |
[44] |
| Nasal: 97 (80.8%) | |||||
| Extranasal: 23 (19.2%) | |||||
|
Intergruppo Italiano Linfomi |
Europe (Italy) |
26 (100%) |
0 (0%) |
26 (100%) |
[39] |
| Nasal: 23 (88.5%) | |||||
| Extranasal: 3 (11.5%) | |||||
|
All series |
423 (94.6%) |
25 (5.6%) |
447 (100%) |
NA |
|
| Nasal: 335 (79.4%) | |||||
| Extranasal: 88 (20.6%) | |||||
Abbreviations: ANKTCL aggressive NK-cell leukemia, NKTCL NK/T-cell Lymphoma, nasal type, NA not applicable.
* Most of the cases presented in this series were from the Japanese survey of NK-cell neoplasms diagnosed between 1994 and 1998, in which 237 cases were registered: 149 nasal-type NK-cell lymphoma (123 nasal and 26 extranasal), 22 aggressive NK-cell leukemia/lymphoma, 19 chronic NK lymphocytosis and 57 cases corresponding to diseases that are not considered as originating from mature NK-cells accordingly to the WHO classification updated in 2008 (11 myeloid/NK-cell precursor acute leukemia, 15 blastic NK-cell lymphoma, 21 precursor NK-cell acute lymphoblastic leukemia) [36].
** Consecutive cases of peripheral T-cell lymphoma (excluding Mycosis Fungoides and Sezary syndrome) and NK/T-cell lymphoma diagnosed between 1990 and 2002. Total number of cases registered: 1153 (Asia: 464, 40.2%; Europe and North America 689, 59.8%). Total number of NK-cell neoplasms registered: 136 (11.8%) (Asia: 104, 76.5%; Europe and North America: 32, 23.5%) (NKTCL: 127; ANKCL: 2; unclassified NK-cell neoplasms: 7).